PBD-monoamide

• Description :

  PBD-monoamide, a modified PBD (pyrrolobenzodiazepine) dimer, is an ADC Cytotoxin. PBD-monoamide can be used for synthesis of DHES0815A (an HER2 ADC) . PBD-monoamide has DNA-binding activity and reduces cell viability[1].

• UNSPSC :

  12352203

• Target :

  ADC Payload

• Type :

  ADC Related

• Related Pathways :

  Antibody-drug Conjugate/ADC Related

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/pbd-monoamide.html

• Purity :

  96.41

• Solubility :

  DMSO : 125 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=CC(OC)=C(OCCCCCOC2=C(OC)C=C3C(N=C[C@@]([H])(N(C3=O)C4)CC4=C)=C2)C=C1NC5=O)N([C@]5(C6)[H])CC6=C

• Molecular Formula :

  C33H36N4O7

• Molecular Weight :

  600.66

• References & Citations :

  [1]Lewis GD, et al. The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results. Nat Commun. 2024 Jan 11;15 (1) :466.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, protect from light, stored under nitrogen)

• Scientific Category :

  ADC Related

• Clinical Information :

  No Development Reported

• CAS Number :

  [2093165-00-3]